Core Antimicrobial Stewardship Curriculum Self - Study

The IDSA Core Antimicrobial Stewardship (CAS) Curriculum was developed to provide infectious diseases (ID) fellows with foundational education and training in Antimicrobial
Stewardship (AS), regardless of ultimate career plans. The self-study version of the curriculum is available to learners who are not currently in a fellowship program and seeking independent study of antimicrobial stewardship.

Access to the curriculum will be provided for two years, and the estimated time of completion is 15 hours.

The Core Antimicrobial Stewardship (CAS) Curriculum was featured in the November 2023 episode of Febrile. Check out the podcast below:

Target Audience

Infectious Disease professionals who desire to learn more about antimicrobial stewardship but are not in a participating fellowship program, no longer in fellowship, or generally would like to gain more knowledge on the subject.

Learning Objectives

Upon completion of this Curriculum, you should be able to:

1. Explain to patients and health care providers the importance of antibiotic stewardship in the care of individual patients and the community at large

2. Model antibiotic stewardship best practices during the clinical care of patients in the inpatient and outpatient setting

3. Structure a conversation to effect change in the antibiotic prescribing patterns of other providers using techniques based in behavioral psychology

4. Describe elements of an effective antibiotic stewardship program and explain the inter-professional collaborations and leadership support necessary for its success

 

Additional Information

AttachmentSize
PDF icon CAS Curriculum Purchasing Information172.72 KB
Course summary
Available credit: 
  • 15.50 ABIM MOC II
  • 15.50 ACPE Pharmacy
  • 15.50 AMA PRA Category 1 Credit(s)™
Course opens: 
06/28/2024
Course expires: 
06/28/2027
IDSA Member cost:
$200.00
Non-member cost:
$300.00
Cost:
$300.00

AS Curriculum Workgroup COI Summary Reviewed April 2017 by Rachel Simmons, MD No conflicts found.

All relevant financial relationships have been mitigated.

NameIndividual's role in activityName of commercial interestNature of Relationship
Advani, SonaliWorkgroup MemberNone 
Armstrong, WendyWorkgroup MemberNone 
Barsoumian, AliceWorkgroup MemberNone 
Beeler, ColeWorkgroup MemberNone 
Bennani, KenzaStaffNone 
Blair, BarbraWorkgroup MemberNone 
Brennan - Krohn, TheaWorkgroup MemberNone 
Bryson - Cahn, ChloeWorkgroup MemberNone 
Cherabuddi, KartikWorkgroup MemberNone 
Fong, GaryWorkgroup MemberCritical Innovations, LLCAdvisory/Consultant Role
Gaston, DavidWorkgroup MemberNone 
Hamilton, KeithWorkgroup MemberNone 
Holubar, MarisaWorkgroup MemberNone 
Huang, MishaWorkgroup MemberNone 
Ince, DilekWorkgroup MemberGilead Science’s Clinical Studies for remdesivir Principal Investigator
  Accelerate DiagnosticsResearch Grants/Contracts
  LeidosResearch Grants/Contracts
Justo, Julie AnnWorkgroup MemberbioMerieuxOther remuneration - Speaker's Bureau
  MerckAdvisory/Consultant Role
  VaxartStocks/Bonds
Kang, AmyWorkgroup MemberNone 
Larnard, JeffWorkgroup MemberNone 
Lee, MatthewWorkgroup MemberNone 
Logan, AshleighStaffNone 
Luther, VeraWorkgroup MemberNone 
MacDougal, ConanWorkgroup MemberNone 
Melia, MichaelWorkgroup MemberMerckOrganizational Benefit
  AllerganOrganizational Benefit
  Pfizer; MelintaOrganizational Benefit
Miller, MattWorkgroup MemberAbbvieHonoraria
  La JollaHonoraria
  MerckResearch Grant/Contract
Moenster, RyanWorkgroup MemberShionogiAdvisory/Consultant Role, Honoraria
  Abbvie/AllerganAdvisory/Consultant Role, Honoraria
  Melinta TherapeuticsAdvisory/Consultant Role, Honoraria
  MerckAdvisory/Consultant Role, Honoraria
Nori, PriyaWorkgroup MemberMerckCo-infections in COVID-19 patients
Paras, MollyWorkgroup MemberNone 
Patel, PayalWorkgroup MemberNone 
Rodvold, KeithWorkgroup MemberBLC USA LPAdvisory/Consultant Role, Honoraria
  VenatoRxAdvisory/Consultant Role, Honoraria
  Medicine Company/Qpex BiopharmaAdvisory/Consultant Role, Honoraria
  Vemco Med Ed. (Merck CME/CPE programs)Advisory/Consultant Role, Honoraria
  DebipharmAdvisory/Consultant Role, Honoraria
  ShionogiAdvisory/Consultant Role, Honoraria
   Unrestricted education grant for CME/CPE Program
  Utility TherapeuticsAdvisory/Consultant Role, Honoraria
  JanssenData Safety Monitoring Board (DSMB)
  Clinartis LLC (projects associated with Spero Therapeutics and Sinovent)Advisory/Consultant Role, Honoraria
  USCAST : US Ctte on Antimicrobial Susceptibility TestingVoting Committee Member
Schooneveld, TrevorWorkgroup MemberRebiotix, MerkResearch Grant
  Thermo - FischerSpeaking
Schwartz, BrianWorkgroup MemberNone 
Spicer, JenniferWorkgroup MemberNone 
Stack, ConorWorkgroup MemberNone 
Stead, WendyWorkgroup MemberNone 
Stohs, EricaWorkgroup MemberReviral LtdResearch Grant
Wiley, ZanthiaWorkgroup MemberNone 
Willis, ZacharyWorkgroup MemberNone 
Shnekendorf, RachelStaffNone 

Vaezi, Liza

Workgroup MemberNone 
Rachel SimmonsReviewerNone 

 

 

 

Accreditation Statement
In support of improving patient care, IDSA is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CME Credit Designation Statement
IDSA designates this enduring material for a maximum of 15 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 15 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Physician participation information will be shared with ABIM through ACCME PARS.

CPE Accreditation Statement for Pharmacists

IDSA is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. ACPE Universal Activity Number (JA0007082-0000-21-004-H01-P) has been assigned to this knowledge-based activity. This activity is acceptable for a maximum of 15 on-demand CPE contact hours (1.5 CEUs) in states that recognize ACPE providers. 

Upon completion of this ACPE-approved activity, participants will receive 15 credits that will be automatically uploaded to their NABP e-Profile section of the CPE Monitor. It is the participant's responsibility to upload the correct NABP number to their profile.

Available Credit

  • 15.50 ABIM MOC II
  • 15.50 ACPE Pharmacy
  • 15.50 AMA PRA Category 1 Credit(s)™
 
Status
Price
Title
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.

Price

IDSA Member cost:
$200.00
Non-member cost:
$300.00
Cost:
$300.00
Please login or register to take this course.

Required Hardware/software

PCs Running Window

  • Windows 10  
  • Microsoft Edge
  • Firefox
  • Google Chrome

Apple Computers Running OSX

  • Safari
  • Firefox
  • Google Chrome